Australian biotech market today 08.04.09
Wednesday, 08 April, 2009
The pharma and biotech index is down one per cent at 3pm today, in line with the rest of the All Ordinaries.
The Big Three – Cochlear (ASX:COH), CSL (ASX:CSL) and ResMed (ASX:RMD) – have followed the rest of the index and are down on today’s trading.
Pharmaxis (ASX:PXS), which yesterday appointed US-based life science investment manager Richard van den Broek to its board, is up 8c to almost $2.
Novogen (ASX:NRT) is also up again today on very small volumes. The company today announced good results from a Phase II trial being carried out by one of its US subsidiaries, Glycotex, in wound healing. While this trial is in a cosmetic application, the company is also investigating its compound GLYC-101 in burns, surgical wounds and venous and diabetic ulcers.
Progen (ASX:PGL) is up again despite its recent dramas, settling at just over 90c today.
API manufacturer IDT Australia (ASX:IDT) is down 6c to $1.52, while Circadian (ASX:CIR) is up 3c and Clinuvel (ASX:CLV) is up 1c.
Shorter radiotherapy course proves safe for prostate cancer
A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...
5-in-1 meningococcal vaccine proves effective
A life-saving meningococcal vaccine covering all five common strains of the deadly disease could...
Diabetes drug reduces knee arthritis pain in overweight patients
A common diabetes drug can reduce the pain of people with knee osteoarthritis and overweight or...
